421 related articles for article (PubMed ID: 26733306)
21. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
22. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
Kim H; Cho U; Hong SH; Park HS; Kim IH; An HJ; Shim BY; Kang JH
Oncol Res; 2024; 32(6):1021-1030. PubMed ID: 38827321
[TBL] [Abstract][Full Text] [Related]
23. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
24. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
Li Y; Zu X; Hu X; Wang L; He W
Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
[TBL] [Abstract][Full Text] [Related]
25. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells.
Liu J; Bi J; Li Z; Li Z; Liu X; Kong C
Int J Mol Med; 2018 Mar; 41(3):1765-1773. PubMed ID: 29328435
[TBL] [Abstract][Full Text] [Related]
26. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
[TBL] [Abstract][Full Text] [Related]
27. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
[TBL] [Abstract][Full Text] [Related]
28. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
[TBL] [Abstract][Full Text] [Related]
30. Suppression of HAX-1 induced by miR-325 resensitizes bladder cancer cells to cisplatin-induced apoptosis.
Li R; Zheng JZ; Huang X
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9303-9314. PubMed ID: 33015771
[TBL] [Abstract][Full Text] [Related]
31. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
32. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
33. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.
Zhu H; Wu J; Zhang W; Luo H; Shen Z; Cheng H; Zhu X
Sci Rep; 2016 Aug; 6():30788. PubMed ID: 27492148
[TBL] [Abstract][Full Text] [Related]
34. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
35. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.
Li H; Yu G; Shi R; Lang B; Chen X; Xia D; Xiao H; Guo X; Guan W; Ye Z; Xiao W; Xu H
Mol Cancer; 2014 Jan; 13():8. PubMed ID: 24423412
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of maspin expression in bladder cancer.
Beecken WD; Engl T; Engels K; Blumenberg C; Oppermann E; Camphausen K; Shing Y; Reinecke G; Jonas D; Blaheta R
World J Urol; 2006 Aug; 24(3):338-44. PubMed ID: 16832651
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.
Narayan V; Vaughn D
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):731-42. PubMed ID: 25604887
[TBL] [Abstract][Full Text] [Related]
39. Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.
Steele TM; Talbott GC; Sam A; Tepper CG; Ghosh PM; Vinall RL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875757
[TBL] [Abstract][Full Text] [Related]
40. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
